Drug Profile
Research programme: asthma/allergy therapy - Affimed Therapeutics
Alternative Names: AFM 19; anti IL-13RLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Affimed Therapeutics
- Class Antibodies
- Mechanism of Action Interleukin 13 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma; Hypersensitivity
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Allergy in Germany
- 04 Nov 2017 No recent reports of development identified for preclinical development in Asthma in Germany
- 26 Jul 2005 Preclinical trials in Allergy in Germany (unspecified route)